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ABSTRACT
Purpose. The aim of this study was to evaluate the influ-
ence of lymph node yield (LNY) on postoperative
mortality and overall survival in elderly patients with
gastric cancer.
Methods. This population-based study included data from
The Netherlands Cancer Registry of patients who under-
went curative gastrectomy for adenocarcinoma between
2006 and 2014. Patients were divided into two groups
based on age (\75 years, young; C75 years, elderly). LNY
was analyzed as both a categorical variable (low, \15
nodes; intermediate, 15–25 nodes; high,[25 nodes), and a
discrete variable. Multivariable analysis was used to eval-
uate the influence of LNY on 30- and 90-day mortality, as
well as overall survival.
Results. A total of 3764 patients were included in the
study; 2387 (63%) were classified as ‘young’, and 1377
(37%) were classified as ‘elderly’. The median LNY was
14 in the young group, compared with 11 in the elderly
group (p\ 0.001). In the elderly group, 851 (62%) patients
had a low LNY, 333 (24%) had an intermediate LNY, and
174 (13%) had a high LNY. Multivariable analysis
demonstrated that in the elderly patients, a higher LNY was
associated with a prolonged overall survival (low: refer-
ence; intermediate: hazard ratio [HR] 0.74, 95% confidence
interval [CI] 0.62–0.88, p\ 0.001; high: HR 0.59, 95% CI
0.45–0.78, p\ 0.001), but not with 30-day (p = 0.940)
and 90-day mortality (p = 0.573). For young patients,
these results were comparable.
Conclusion. In both young and elderly patients, a high
LNY is associated with prolonged survival but not with an
increase in postoperative mortality. Therefore, an extensive
lymphadenectomy is the preferred strategy for all patients
during gastrectomy in order to provide an optimal onco-
logical result.
Worldwide, surgical treatment of gastric adenocarcinoma
consists of resection of the stomach combined with a lym-
phadenectomy to remove both macro- and micrometastases
of the tumor.1 In the past, several studies have compared a
D1 lymphadenectomy, including perigastric lymph nodes,
with a D2 lymphadenectomy, including both perigastric
lymph nodes and locoregional lymph nodes. These studies
found a survival benefit of D2 lymphadenectomy over D1
lymphadenectomy.2,3 As a result, international guidelines
recommend D2 lymphadenectomy for all advanced-stage
tumors (cT2-4 or cN?).4,5
Elderly patients undergoing major cancer surgery are
prone to postoperative morbidity and mortality due to pre-
existent comorbidities.6 Additionally, in some studies a
more extensive lymphadenectomy has been associated with
higher postoperative morbidity and mortality.7,8 These
short-term outcomes may be more relevant in elderly
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patients as the expected survival benefit from an extensive
lymphadenectomy is lower compared with younger
patients. As elderly patients form a substantial portion of
the patients undergoing gastrectomy for cancer,9 the extent
of lymphadenectomy in the elderly is currently under
debate.
Lymph node yield (LNY) has frequently been used as a
surrogate for the extent of lymphadenectomy.10 Therefore,
the current study aimed to evaluate the influence of LNY
on postoperative mortality and overall survival in both
young and elderly patients with gastric cancer.
MATERIALS AND METHODS
Study Design
This population-based observational cohort study
included data from The Netherlands Cancer Registry
(NCR), which has an area comprising nearly 17 million
inhabitants. In The Netherlands, all newly diagnosed can-
cers are registered in the NCR, which is maintained by the
Netherlands Comprehensive Cancer Organisation (IKNL).
The National Automated Pathology Archive (PALGA) and
the National Registry of Hospital Discharge Diagnoses are
important sources for the NCR. Trained data managers
register data from hospital records within all Dutch hos-
pitals on a daily basis using the NCR’s registration and
coding manual, and survival status is updated yearly from
the civil registry. The NCR’s privacy committee approved
this study.
Patients
In this study, data from patients who underwent a curative
gastrectomy for gastric adenocarcinoma (pT0-4a, N0-3, M0)
during the period 2006–2014 were selected from the NCR.
Patients who underwent multi-organ surgery and patients
without follow-up were excluded. Data on patient and
treatment-related characteristics, histopathological charac-
teristics, and follow-up were extracted from the NCR,
whereas data regarding patients’ comorbidities and postop-
erative morbidity were not available from the NCR.
Diagnosis, Treatment, and Follow-Up
Patients were diagnosed and treated according to the Dutch
national guidelines for the diagnosis, treatment, follow-up,
and guidance of patients with gastric cancer.11 The diagnostic
work-up consisted of endoscopy with tumor biopsy and
computed tomography (CT). In most cases, patients who
underwent neoadjuvant chemotherapy received a regimen
comparable to epirubicin, cisplatin, and capecitabine.12 Since
2010, gastric surgery has been centralized in The Nether-
lands, aiming for a minimum of 20 procedures per center per
year.13 Surgery consisted of a subtotal or total gastrectomy,
depending on the possibility of achieving a proximal resec-
tion margin of C6 cm.11 In all patients, national guidelines
recommended a D2 lymphadenectomy without station 10
dissection, pancreatectomy, and splenectomy, but the NCR
did not include information on the actual lymphadenectomy
performed. Resection specimens were reviewed by patholo-
gists in accordance with the Union for International Cancer
Control (UICC) TNM staging system.14 Tumors that were
staged according to the 6th edition were translated to the 7th
edition.5 The routine follow-up of patients consisted of
medical history and physical examination at the outpatient
clinic after 6 weeks, 6 months, 12 months, and yearly
thereafter until discharge of follow-up after 5 years. Radio-
logical imaging was not routinely performed during follow-
up.
Outcome Measures
All included patients were divided into two groups
based on age according to a previous study;10 patients
younger than 75 years (\75 years group, young) and
patients aged 75 years or older (C75 years group, elderly).
The LNY was categorized into three groups according to a
previous study:10 low (\15 nodes), intermediate (15–25
nodes), and high ([25 nodes) LNY. (Sub) acute surgery
was defined as surgery within\7 days after diagnosis, and
postoperative mortality was analyzed within 30- and
90-days after surgery. Overall survival was calculated in
months from the day of surgery until death or the end of
follow-up on 31 December 2015.
Statistical Analyses
To assess the distribution of all baseline, surgical, and
histopathological characteristics, a comparison was made
between the three groups of LNYs (\15, 15–25, and[25
nodes). Categorical variables were analyzed using the v2
test and continuous variables were compared using one-
way analysis of variance (ANOVA). To evaluate the
influence of LNY on postoperative mortality, univariable
and multivariable logistic regression analysis was per-
formed, providing odds ratios (ORs) with 95% confidence
intervals (CIs). In addition, the influence of LNY on overall
survival was evaluated using univariable and multivariable
Cox proportional hazards models, providing hazard ratios
(HRs) along with 95% CIs. For the multivariable Cox
analysis, a nonparsimonious approach was used for the
selection of model variables, including all patient- and
treatment-related characteristics, as well as LNY. LNY was
included as both a categorical variable and a discrete
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TABLE 1 Baseline characteristics of 3764 patients who underwent gastrectomy with curative intent for cancer, stratified by age (\75 and
C75 years)
All Young (\75 years) Elderly (C75 years) p value
n = 3764 (%) n = 2387 (%) n = 1377 (%)
Age, years (mean [SD]) 68.7 [±11.8] 62.3 [9.9] 80.0 [3.8] \0.001
Sex 0.058
Male 2305 (61) 1489 (62) 816 (59)
Female 1459 (39) 898 (38) 561 (41)
Malignancy history \0.001
No 3265 (87) 2140 (90) 252 (18)
Yes 499 (13) 247 (10) 1125 (82)
Referral for gastrectomy \0.001
No 2720 (80) 1647 (77) 1073 (86)
Yes 659 (20) 481 (23) 178 (14)
Unknown 385 259 126
Year of diagnosis \0.001
2006–2008 1317 (35) 807 (34) 510 (37)
2009–2011 1229 (33) 747 (31) 482 (35)
2012–2014 1218 (32) 833 (35) 385 (28)
Neoadjuvant treatment \0.001
None 2169 (58) 967 (41) 1202 (87)
Chemotherapy 1567 (42) 1400 (59) 167 (12)
Radiotherapy 4 (0.1) 0 (0) 4 (0.3)
Chemoradiation 24 (0.6) 20 (0.8) 4 (0.3)
Surgical urgency 0.014
(Sub)acute 157 (4) 85 (4) 72 (5)
Elective 3607 (96) 2302 (96) 1305 (95)
Surgical type \0.001
Subtotal gastrectomy 2438 (65) 1438 (60) 1000 (73)
Total gastrectomy 1326 (35) 949 (40) 377 (27)
Surgical approach 0.032
Open 3377 (91) 2120 (90) 1238 (92)
Laparoscopic 347 (9) 238 (10) 109 (8)
Unknown 40 29 30
Radicality 0.948
R0 3164 (87) 2006 (87) 1158 (87)
R? 461 (13) 293 (13) 168 (13)
Rx 139 88 51
(y)pT stage \0.001
T0 118 (3) 102 (4) 16 (1)
T1 720 (19) 470 (20) 250 (18)
T2 637 (17) 386 (16) 251 (18)
T3 1434 (39) 900 (38) 534 (39)
T4a 811 (22) 494 (21) 317 (23)
Tx 44 35 9
(y)pN stage 0.729
N0 1856 (49) 1173 (49) 683 (50)
N1 689 (18) 440 (18) 249 (18)
N2 604 (16) 389 (16) 215 (16)
N3 615 (16) 395 (16) 230 (17)
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variable. Results were stratified according to age (\75 and
C75 years), and a subgroup analysis was performed based
on the radicality of the resection (R0/R?). For all Cox
proportional hazard models, nonviolation of the propor-
tional hazards assumption was verified with log-minus-log




The NCR selected data from 3814 patients who under-
went a curative gastrectomy for gastric adenocarcinoma; a
total of 50 patients were excluded as a result of multi-organ
surgery (n = 45) or lack of follow-up (n = 5). Of the
remaining 3764 patients, 2387 (63%) were younger than 75
years of age and 1377 (37%) were aged 75 years or older.
Patient and treatment-related characteristics and their
comparison between young and elderly patients are pre-
sented in Table 1.
Lymph Node Yield
In young patients, the median LNY was 14 (interquartile
range [IQR] 8–22), compared with 11 (IQR 6–18) in
elderly patients (p\ 0.001). In the elderly patients, 851
(62%) had a low LNY, 333 (24%) had an intermediate
LNY, and 174 (13%) had a high LNY; no data on LNY
were available for 19 (1%) patients. In the young patients,
1180 (49%) had a low LNY, 707 (30%) had an interme-
diate LNY, and 462 (19%) had a high LNY; no data were
available for 38 (2%) patients. Comparison of patient- and
treatment-related characteristics between the different
LNY groups are presented in Table 2.
Postoperative Mortality
The 30- and 90-day mortality in the total study popu-
lation was 5 and 8%, respectively, and both the 30- and
90-day mortality rates were higher in elderly patients
compared with young patients (30-day mortality 10 vs. 3%,
p\ 0.001; 90-day mortality 14 vs. 5%, p\ 0.001,
respectively). In elderly patients, the 30-day mortality
within the low (\15), intermediate (15–25), and high ([25)
LNY groups was 10, 10, and 8%, respectively, whereas the
90-day mortality was 15, 14, and 10%, respectively. Mul-
tivariable analysis did not demonstrate an association
between LNY and postoperative mortality for both young
and elderly patients (p[ 0.25) (Table 3).
Overall Survival
The median overall survival of all patients was 41 months;
58 months in young patients compared with 27 months in
elderly patients. The median survival of elderly patients in the
low (\15), intermediate (15–25), and high ([25) LNY groups
was 26, 26, and 31 months, respectively (p = 0.228), whereas
the median survival of young patients was 61, 58, and
52 months, respectively (p = 0.482). In multivariable analysis,
a higher LNY in elderly patients was significantly associated
with a prolonged survival when analyzed as a discrete variable
(each additional node: HR 0.98, 95% CI 0.97–0.99, p\0.001)
or a categorical variable (\15 nodes: reference; 15–25 nodes:
HR 0.74, 95% CI 0.62–0.88, p\0.001;[25 nodes: HR 0.59,
95% CI 0.45–0.78, p\0.001). These results were comparable
for young patients (Table 4). Figure 1 shows the adjusted
survival curves of elderly and young patients, stratified by
LNY. Subgroup analysis demonstrated that R status did not
influence the association between LNY and overall survival
(data not shown).
TABLE 1 continued
All Young (\75 years) Elderly (C75 years) p value
n = 3764 (%) n = 2387 (%) n = 1377 (%)
Tumor differentiation \0.001
Well 100 (4) 53 (3) 47 (4)
Moderate 722 (27) 366 (23) 356 (32)
Poor 1886 (70) 1165 (74) 721 (64)
Undifferentiated 1 (\0.1) 1 (\0.1) 0 (0)
Unknown 1055 802 253
Adjuvant therapy \0.001
No 2736 (73) 1433 (60) 1303 (95)
Chemotherapy 790 (21) 740 (31) 50 (4)
Chemoradiation 238 (6) 214 (9) 24 (2)
Bold values indicate significance (p\ 0.05). Values were rounded to the nearest percentage point
SD standard deviation
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DISCUSSION
This population-based observational cohort study aimed
to evaluate the influence of LNY on postoperative mor-
tality and overall survival in patients aged 75 years or older
who underwent curative gastrectomy for cancer. The
results indicate that a high LNY improves survival for both
young and elderly patients. In addition, LNY was not
associated with postoperative mortality in these patients.
The findings of the present study are in line with several
large population-based studies investigating the effect of
LNY on survival.15,16 One of these studies found a linear
trend for improved survival based on more harvested
nodes, up to a cut-off point of 40 lymph nodes.15 More-
over, other studies demonstrated that in patients with a low
LNY, no adequate prediction of patient survival could be
made, suggesting inadequate staging.17,18 International and
national guidelines therefore require examination of C15
lymph nodes for adequate staging of gastric cancer.9,14
As elderly form a substantial portion of gastric cancer
patients9 and are prone to postoperative morbidity and
mortality,6 the extent of lymphadenectomy in elderly
patients with gastric cancer has been under debate.
Recently, a French study did not find a difference in sur-
vival between a high, low, and intermediate LNY in
patients aged 75 years and older who underwent curative
gastrectomy for cancer.10 Even though a higher LNY did
not affect postoperative morbidity and mortality, the
authors advise a limited lymphadenectomy due to the lack
of a survival benefit. However, the effect of LNY on the
outcomes was assessed in univariable analysis only, which
does not allow for correction of well-known confounders
such as patient and tumor characteristics. Such confounders
may introduce bias, which is a challenging problem in
retrospective observational studies.19 These limitations, as
well as the possible implications of the authors’ recom-
mendations on daily practice, made evaluation of these
findings warranted. The present study has taken these
limitations into account by including almost four times as
many elderly patients from a more recent cohort, and by
performing a multivariable analysis. The current results
confirm the absence of increased postoperative mortality,
but support the oncological value of an extensive lym-
phadenectomy in all patients undergoing curative
gastrectomy for cancer with a clear survival benefit.
The present study chose a cut-off point of 75 years to be
able to make a fair comparison with the French study;
however, the definition of ‘elderly’ is arbitrary and we do
not believe that age should be a ‘hard-stop’ discriminator
for the choice of the extent of treatment. In our opinion,
patient fitness rather than age should be considered when
choosing the appropriate treatment. For patient fitness,
factors such as comorbidities, smoking status, and weight
loss should be taken into account.20
TABLE 3 Univariable and multivariable logistic regression analyses on the influence of lymph node retrieval on 30-and 90-day mortality in
patients treated with gastrectomy for cancer, stratified for age (\75years and C75 years)
Young (\75 years) 30-day mortality 90-day mortality
Univariable Multivariablea Univariable Multivariablea
OR 95% CI p value OR 95% CI p value OR 95% CI p value OR 95% CI p value
Each additional node 0.99 0.97–1.02 0.445 0.99 0.96–1.02 0.521 0.99 0.97–1.01 0.183 0.99 0.96–1.01 0.298
\15 nodes Ref – – Ref – – Ref – – Ref – –
15–25 nodes 0.72 0.40–1.30 0.269 0.65 0.32–1.32 0.236 0.71 0.45–1.11 0.134 0.81 0.47–1.37 0.429
[25 nodes 0.82 0.43–1.59 0.565 0.85 0.36–1.99 0.701 0.74 0.44–1.24 0.250 0.74 0.37–1.48 0.400
Elderly (C75 years) 30-day mortality 90-day mortality
Univariable Multivariablea Univariable Multivariablea
OR 95% CI p value OR 95% CI p value OR 95% CI p value OR 95% CI p value
Each additional node 0.99 0.97–1.01 0.173 1.00 0.98–1.03 0.940 0.99 0.97–1.01 0.173 0.99 0.97–1.02 0.573
\15 nodes Ref – – Ref – – Ref – – Ref – –
15–25 nodes 0.85 0.59–1.22 0.367 0.94 0.56–1.58 0.823 0.85 0.59–1.22 0.367 0.87 0.55–1.36 0.538
[25 nodes 0.66 0.38–1.14 0.132 0.74 0.34–1.60 0.442 0.66 0.38–1.14 0.132 0.63 0.32–1.23 0.178
a Adjusted for age, sex, malignancy history, referral, year of diagnosis, tumor differentiation, neoadjuvant therapy, surgical urgency, type of
surgery, surgical approach, radicality, (y)pT stage, and (y)pN stage
OR odds ratio, CI confidence interval
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TABLE 4 Univariable and multivariable Cox regression analyses on the influence of lymph node retrieval on overall survival in patients treated
with gastrectomy for cancer, stratified for age (\75 years and C75 years)
Young (\75 years) Elderly (C75 years)
Univariable Multivariablea Univariable Multivariablea
HR 95% CI p value HR 95% CI p value HR 95% CI p value HR 95% CI p value
Lymph node yield
\15 nodes Ref – – Ref – – Ref – – Ref – –
15–25 nodes 0.97 0.85–1.11 0.68 0.71 0.60–0.83 \0.001 1.03 0.88–1.21 0.69 0.75 0.63–0.89 0.001
[25 nodes 1.07 0.91–1.26 0.41 0.62 0.51–0.76 \0.001 0.83 0.67–1.04 0.10 0.61 0.47–0.80 \0.001
Additional year of age 1.01 1.00–1.02 0.001 1.01 1.00–1.02 0.008 1.04 1.03–1.06 \0.001 1.03 1.02–1.05 \0.001
Sex
Male Ref – – Ref – – Ref – – Ref – –
Female 1.001 0.89–1.13 0.982 1.07 0.94–1.22 0.325 0.91 0.80–1.04 0.180 0.80 0.69–0.92 0.002
Malignancy history
No history of malignancy Ref – – Ref – – Ref – – Ref – –
Malignancy in history 1.21 1.01–1.45 0.043 1.20 0.98–1.46 0.076 1.21 1.03–1.42 0.021 1.38 1.15–1.64 \0.001
Referral
Same hospital Ref – – Ref – – Ref – – Ref – –
Other hospital 0.98 0.85–1.14 0.812 0.99 0.83–1.17 0.859 1.04 0.85–1.26 0.730 1.23 0.99–1.54 0.064
Additional year of diagnosis 1.00 0.97–1.02 0.790 1.06 1.02–1.09 0.002 0.96 0.93–0.99 0.003 0.98 0.95–1.02 0.360
Tumor differentiation
Well Ref – – Ref – – Ref – – Ref – –
Moderate 1.88 1.12–3.13 0.016 0.97 0.57–1.65 0.897 1.07 0.72–0.60 0.739 0.84 0.55–1.28 0.415
Poor 2.31 1.41–3.80 0.001 0.95 0.56–1.59 0.831 1.73 1.18–2.55 0.006 1.07 0.71–1.61 0.756
Undifferentiated 3.95 0.52–29.8 0.182 0.87 0.51–1.48 0.608 NA NA NA NA NA NA
Neoadjuvant therapy
None Ref – – Ref – – Ref – – Ref – –
Chemotherapy 0.83 0.74–0.93 0.001 1.10 0.93–1.29 0.264 0.63 0.50–0.79 \0.001 0.94 0.69–1.27 0.682
Chemoradiotherapy 0.78 0.39–1.57 0.485 0.42 0.14–1.32 0.139 2.49 0.93–6.65 0.070 2.92 0.91–1.46 0.072
Surgical urgency
Elective Ref – – Ref – – Ref – – Ref – –
(Sub)acute 1.44 1.09–1.90 0.011 1.16 0.85–1.58 0.342 1.22 0.92–1.60 0.168 1.11 0.82–1.50 0.501
Type of surgery
Partial Ref – – Ref – – Ref – – Ref – –
Total 1.41 1.26–1.59 \0.001 1.27 1.11–1.45 \0.001 1.29 1.12–1.49 \0.001 1.25 1.07–1.46 0.005
Surgical approach
Open Ref – – Ref – – Ref – – Ref – –
Minimally invasive 0.93 0.73–1.18 0.54 0.98 0.72–1.33 0.901 0.88 0.65–1.18 0.391 0.96 0.64–1.45 0.849
Radicality
R0 Ref – – Ref – – Ref – – Ref – –
R1 3.18 2.74–3.70 \0.001 1.65 1.39–1.96 \0.001 2.38 1.99–2.84 \0.001 0.45 1.18–1.77 \0.001
R2 6.60 4.13–10.5 \0.001 1.95 1.11–3.45 0.021 3.98 2.24–7.05 \0.001 2.32 1.20–4.48 0.012
(y)pT stage
T0 Ref – – Ref – – Ref – – Ref – –
T1 1.17 0.67–2.06 0.579 1.07 0.57–2.02 0.839 1.22 0.50–3.00 0.655 0.91 0.32–2.60 0.854
T2 2.45 1.42–4.25 0.001 1.80 1.97–3.36 0.064 1.63 0.67–3.97 0.258 1.09 0.38–3.10 0.872
T3 5.34 3.14–9.08 \0.001 3.20 1.74–5.87 \0.001 3.03 1.25–7.32 0.014 1.57 0.56–4.43 0.396
T4a 7.65 4.48–13.0 \0.001 3.68 1.96–6.81 \0.001 4.19 1.73–10.1 0.002 1.85 0.65–5.26 0.249
(y)pN stage
N0 Ref – – Ref – – Ref – – Ref – –
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Interestingly, LNY increased over the years, especially
in the last period (2012–2014). In The Netherlands, a D2
lymphadenectomy has been standard of care since the final
publication of the Dutch D1–D2 trial;21 therefore, a D2
lymphadenectomy was recommended throughout the
whole study period. It could be that surgical quality
increased over the years due to centralization of stomach
surgery in The Netherlands (started in 2009), but no data
are currently available to support this hypothesis. Another
factor is the start of the Dutch Upper GI Cancer Audit
(DUCA) in 2011, which has contributed to an increase in
LNY.22 In the DUCA, LNY ([15 nodes) is seen as an
important quality indicator, which may have motivated
centers to increase their LNY.22 This increase may then be
due to an improvement in surgical quality, but could also
be attributed to a more thorough inspection of the resection
specimen by pathologists.
It is important to realize that LNY does not fully cor-
respond to the extent of lymphadenectomy. Although a D2
lymphadenectomy is recommended by national and inter-
national guidelines,11,23 the Dutch D1–D2 trial
demonstrated that more than half of the resection speci-
mens, which were indicated to have had a D2
lymphadenectomy, lacked two or more of the required
lymph node stations.24 On the other hand, one-quarter of
these resection specimens included more than the intended
lymph nodes stations. These results indicate that both the
French study and the current study do not know exactly
which lymphadenectomy was actually performed by the
surgeons. In addition to these uncertainties, there might be
variation in lymphadenectomy between surgeons, variation
in the submission of specimens (en bloc or in separate
containers),25 and variation in lymph node retrieval by
pathologists,26 all of which may influence the final LNY.
All these factors combined imply that caution should be
taken in drawing conclusions on the extent of lym-
phadenectomy, based solely on counting lymph nodes. In
addition, the applicability of LNY as a surrogate for lym-
phadenectomy without data on tumor recurrence should be
carefully interpreted. Ideally, a randomized controlled trial
comparing different types of lymphadenectomies in elderly
patients should be performed in order to provide a fair
answer to this topic. On the other hand, such a study might
not be considered ethical regarding the favorable results of
an extensive lymphadenectomy,7,27 especially since post-
operative mortality seems not to be increased as a result of
the lymphadenectomy.
Although the present study corrected for many con-
founding factors, including patient and tumor
characteristics, data on patients’ comorbidities, American
Society of Anesthesiologists (ASA) status, body mass
index (BMI), and disease recurrence were not available
from the NCR database. Therefore, we could not correct
for these well-known patient confounders, which could
have influenced the extent of lymphadenectomy performed
(selection bias), nor could we investigate the influence of
LNY on disease-free survival. For instance, patients with
poor performance status or severe comorbidities might
have undergone a less extended lymphadenectomy.
Moreover, NCR data lack information on the type of
chemotherapy and the number of cycles, and administra-
tion of palliative chemotherapy is absent. Palliative
chemotherapy has been shown to improve survival com-
pared with supportive care.28 As a large number of patients
develop distant metastases, the use of systemic therapy
may influence survival. Furthermore, no data on hospital
volume were available, which may influence both LNY and
postoperative outcomes. Lastly, there might be some
unknown confounding due to the retrospective nature of
the study.
TABLE 4 continued
Young (\75 years) Elderly (C75 years)
Univariable Multivariablea Univariable Multivariablea
HR 95% CI p value HR 95% CI p value HR 95% CI p value HR 95% CI p value
N1 2.29 1.94–2.69 \0.001 1.71 1.43–2.06 \0.001 1.86 1.58–2.56 \0.001 1.60 1.31–1.96 \0.001
N2 3.28 2.79–3.85 \0.001 2.43 2.02–2.92 \0.001 2.54 2.11–3.05 \0.001 2.10 1.71–2.58 \0.001
N3a 4.82 4.06–5.74 \0.001 3.65 2.97–4.48 \0.001 4.18 3.46–5.05 \0.001 3.26 2.59–4.10 \0.001
N3b 8.99 8.99–7.10 \0.001 6.38 4.74–8.59 \0.001 5.02 3.65–6.90 \0.001 4.81 3.27–7.09 \0.001
Adjuvant therapy
None Ref – – Ref – – Ref – – Ref – –
Chemotherapy 0.71 0.62–0.81 \0.001 0.67 0.56–0.79 \0.001 0.53 0.35–0.82 0.005 0.73 0.43–1.23 0.241
Chemoradiotherapy 0.94 0.77–1.16 0.575 0.70 0.56–0.88 0.002 0.94 0.57–1.57 0.825 0.43 0.24–0.78 0.005
Bold values indicate significance (p\ 0.05)
HR hazard ratio, CI confidence interval, NA not applicable
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CONCLUSION
A high LNY is associated with prolonged survival but
not with an increase in postoperative mortality, for young
as well as elderly patients. Therefore, an extensive lym-
phadenectomy cannot be abandoned as the preferred
strategy and should be considered in all patients during
gastrectomy.
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